# AG-120 in People With IDH1 Mutant Chondrosarcoma

> **NCT04278781** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Chondrosarcoma
- Chondrosarcoma, Grade 2
- Chondrosarcoma, Grade 3
- IDH1 Gene Mutation

## Interventions

- **DRUG:** AG-120

## Key facts

- **NCT ID:** NCT04278781
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-04
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04278781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04278781, "AG-120 in People With IDH1 Mutant Chondrosarcoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04278781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*